Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease
Veronika Bachanová(University of Minnesota), Daniel J. Weisdorf(University of Minnesota), Edmund K. Waller(Emory University), Martha Arellano(Memorial Sloan Kettering Cancer Center), Edward A. Copelan(Levine Cancer Institute), Hai‐Lin Wang(Medical College of Wisconsin), Ravi Vij(Washington University in St. Louis), Y-B Chen(Harvard University Press), Marcos de Lima(The Ohio State University), Alison W. Loren(University of Pennsylvania), Hillard M. Lazarus(University Hospitals of Cleveland), M-J Zhang(Medical College of Wisconsin), Victor Lewis(Alberta Children's Hospital), Andrew Artz, Wael Saber(Medical College of Wisconsin), Alan M. Miller(Baylor College of Medicine), Vikas Gupta(Indian Institute of Technology Kanpur), Jacob M. Rowe(Technion – Israel Institute of Technology), Partow Kebriaei(The University of Texas MD Anderson Cancer Center), Ulrike Bacher(Hattiesburg Clinic), Jane L. Liesveld(Strong Memorial Hospital), William R. Drobyski(Medical College of Wisconsin), Mahmoud Aljurf(King Faisal Specialist Hospital & Research Centre), Betül Oran(The University of Texas MD Anderson Cancer Center), Mark R. Litzow(Mayo Clinic in Arizona), Robert Peter Gale(Imperial College London), Bipin N. Savani(Vanderbilt University Medical Center), Peter H. Wiernik(Albert Einstein College of Medicine), Ian D. Lewis, J-Y Cahn(Université Joseph Fourier), Joseph Pidala(Moffitt Cancer Center), D I Marks, John P. Greer(Vanderbilt University Medical Center), Gregory A. Hale(Johns Hopkins University), Maxim Norkin(Centre Hospitalier Universitaire Vaudois)
Cited by 136
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k